NasdaqGS:INCYBiotechs
Assessing Incyte (INCY) Valuation After FDA Wins For Jakafi XR Opzelura And Pancreatic Cancer Therapy
Incyte (INCY) stock is in focus after the US FDA approved once daily Jakafi XR, along with positive Phase 3 Opzelura data in atopic dermatitis and orphan drug designation for a pancreatic cancer therapy.
See our latest analysis for Incyte.
Despite a 1-day share price decline of 2.08% to about $97.77, Incyte’s 63.69% 1-year total shareholder return and recent FDA wins suggest momentum has been building around its pipeline and diversification efforts.
If recent oncology and dermatology updates...